ZYBERNO
Stock Report
Updated Sep 1, 2026

LISATA THERAPEUTICS, INC. (LSTA)

Healthcare • NASDAQ

$1.49

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
25.0/100
POOR BUSINESS
LISATA THERAPEUTICS, INC. (LSTA) scores 25/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-102.2%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.01x)
Operating Margin (Operational Efficiency):CRITICAL (-8,292.4%)
Return on Capital (Capital Efficiency):CRITICAL (-1,810.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LISATA THERAPEUTICS, INC. (LSTA) stock report — Zyberno Score 25/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.49
Market Cap:$13.57M

Valuation Multiples (3)

P/B Ratio:1.70x
P/S Ratio:79.81x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.17M

Price Action & Momentum (1)

% of 52-Week High:29.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-79.8%
Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-20.2%

Margin Analysis (3)

Operating Margin Ttm:-8,292.4%
Net Margin Ttm:-7,575.3%
Ebitda Margin:-8,201.2%

TTM Performance (2)

Operating Margin Ttm:-8,292.4%
Net Margin Ttm:-7,575.3%

Yield Metrics (2)

Earnings Yield:-$122.32
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:49.1%
Latest Earnings Filed:2026-08-06
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.69x
Quick Ratio:3.69x
Cash Ratio:3.50x

Leverage Analysis (3)

Debt To Equity Ttm:0.01x
Debt-to-Equity Ratio:0.01x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:8,026,000.00
Cash And Cash Equivalents:10,443,000.00
Long Term Debt:$50.00K
Net Debt:-$10.39M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$170.00K
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$14.10M

Bottom Line Performance (3)

-$12.88M
Income Before Tax:-$13.43M
Ebitda Ttm:-13,942,000.00

Operating Expenses (5)

Operating Expenses:14,267,000.00
R And D Expense:9,154,000.00
Sga Expense:10,955,000.00
Income Tax Expense:-$551.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-8,201.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$11.03M
Current Assets:$11.01M
Ppe Net:494,000.00
Goodwill:0.00
Intangible Assets:$400.00K

Liability Structure (4)

Total Liabilities:3,037,000.00
Current Liabilities:2,987,000.00
Long Term Debt:$50.00K
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$7.99M
Retained Earnings:-$572.07M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:502,000.00
Inventory:0.00
Accounts Payable:836,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:214,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$15.95M-$15.98M

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$181.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:155,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.37
-$1.37
Earnings Per Share Ttm:-$1.41

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.02
Operating Cash Flow Per Share:-$1.75

Book Value & Capital (2)

Book Value Per Share:$0.88
Cash Per Share:1.15

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:0.02x

Receivables Management (2)

Receivables Turnover Ttm:0.34x
Days Sales Outstanding Ttm:1,077.82

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:1,794.94
Cash Conversion Cycle:-1,716.12
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.1%
Fundamental Growth Rate (g):-20.2%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-41.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:LSTA
Company Name:LISATA THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:9.11M
Shares Outstanding Basic:9.11M
Shares Outstanding Diluted:9.11M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 07:44:24 UTC
Data Timestamp:2026-08-20T20:02:20.042313
Scroll to Top